Waldencast plc (WALD) Form 6-K — Jun 1, 2026
Waldencast plc has entered into a definitive agreement to sell its Obagi Medical business to a consortium led by Waypoint Bidco and Gore Range Capital for total consideration of up to $460 million. The deal structure includes $366 million in cash, $30 million in vendor notes, and up to $64 million in earnout payments based on future revenue milestones for non-injectables and injectables products. The transaction coincides with the departure of Waldencast’s CEO Michel Brousset and Chief Growth Officer Hind Sebti, who will resign at closing but commit to reinvesting $6 million into the buyer’s entity.
Key figures
- Deal Value Usd
- 460000000
- Max Earnout
- 64000000
- Escrow Amount
- 3000000
- Fixed Vendor Note
- 10000000
- Base Purchase Price
- 396000000
- Cash Consideration
- 366000000
- Adjustable Vendor Note
- 20000000
- Reverse Termination Fee
- 16000000
- Key Executive Reinvestment
- 6000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.